Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE)

Trial Profile

Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE)

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 25 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone acetate (Primary) ; Celecoxib (Primary) ; Docetaxel (Primary) ; Enzalutamide (Primary) ; Estradiol (Primary) ; Metformin (Primary) ; Zoledronic acid (Primary) ; Antiandrogens; Apalutamide; Degarelix; Goserelin; Leuprorelin; Prednisolone; Prednisone; Triptorelin
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms STAMPEDE
  • Most Recent Events

    • 20 Jun 2024 Planned End Date changed from 1 Dec 2030 to 31 Mar 2025.
    • 01 Jan 2024 Results from NCT00303784 and NCT00268476 assessing androgen suppression, quality of life and bone health indices and cardiovascular events , published in the Clinical Oncology
    • 24 Oct 2023 Results (n=1791) assessing long-term risk of obstructive uropathy in metastatic hormone sensitive prostate cancer with follow-up to Mar 2021 for patients randomised 1:1 in England between arms A (standard of care [SOC]) and H (SOC+RT) presented at the 48th European Society for Medical Oncology Congress
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top